Novartis says the production site in Wehr, Germany, which manufactures tablets and capsules, is no longer competitive.
Keystone-SDA
Swiss drugmaker Novartis says it will cut around 220 jobs in Germany as part of the planned closure of a production site in Wehr by the end of 2028.
Listen to the article
Listening the article
Toggle language selector
English (US)
English (British)
Generated with artificial intelligence.
This content was published on
May 6, 2026 – 09:41
+Get the most important news from Switzerland in your inbox
Novartis says the production site in Wehr, Germany, which manufactures tablets and capsules, is no longer competitive.
“We are aware of the uncertainty that this announcement brings to our colleagues in Wehr,” Steffen Lang, head of production at Novartis, said in a statement.
The group promises transparent and respectful cooperation with employees and the municipal authorities concerned.
More
More
New treatments
Swiss pharma firm Novartis plans seventh US plant
This content was published on
Apr 30, 2026
Novartis is expanding its production capacity in the United States, with the announcement of a new site in Morrisville, North Carolina. This plant will bring to seven the number of new sites planned as part of its $23 billion investment plan.
Read more: Swiss pharma firm Novartis plans seventh US plant
Novartis assures that the closure will not jeopardise patient supplies and reaffirms its commitment to Germany, where the company employs 2,600 staff at six sites.
Meanwhile, Novartis has announced that it will invest €35 million (CHF32 million) in a new cancer therapy plant in Halle, Saxony-Anhalt, which is expected to be operational in 2027.
More
More
Healthcare innovation
US trade deal forces reckoning for Swiss pharma powerhouse
This content was published on
Nov 18, 2025
Swiss pharma made massive investment promises to the US that are fueling anxiety about the industry’s future in Switzerland.
Read more: US trade deal forces reckoning for Swiss pharma powerhouse
Adapted from French by AI/sb
How we work
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
Articles in this story